Novel Peptide Shows Strong Potential for Treating Low Sexual Desire in Women

Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting millions of women, characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity. Existing pharmacological treatments for HSDD have limited efficacy and significant side effects, highlighting an urgent need for novel, targeted therapies. This study specifically addresses the lack of highly effective and well-tolerated treatments by investigating a new neuropeptide agonist.

Treatment with LibidoMax-P resulted in a statistically significant and clinically meaningful improvement in sexual desire compared to placebo. The LibidoMax-P group demonstrated an average increase of 3.1 points in the FSFI desire domain score from baseline, whereas the placebo group showed only a 0.8-point increase (p<0.0001). A key finding was that 65% of women treated with LibidoMax-P reported a clinically meaningful improvement in their sexual desire, defined as an increase of 1.2 points or more on the FSFI desire domain, compared to just 22% in the placebo group (p<0.0001), representing a 2.95-fold higher response rate. Furthermore, participants receiving LibidoMax-P experienced a 2.7-fold increase in the frequency of satisfying sexual events per month from baseline, significantly higher than the 1.1-fold increase observed in the placebo group (p<0.001). Adverse events were generally mild, with 15% reporting transient nausea in the LibidoMax-P group versus 5% in placebo.